Seminars in urologic oncology最新文献_第2页

Chemotherapy for androgen-independent prostate cancer. 雄激素非依赖性前列腺癌的化疗。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/suro.2002.35052

D. Petrylak

引用次数: 57

Detection and characterization of renal masses and staging of renal cancers: new considerations in the era of helical computed tomography. 肾肿块的检测、表征和肾癌的分期:螺旋ct时代的新考虑。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/suro.2002.35332

Richard H Cohan

引用次数: 1

Imaging for nephron-sparing surgery. 肾保留手术的影像学检查。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/suro.2002.35330

Erick M Remer, Brian R Herts, Joseph C Veniero

引用次数: 7

Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer. 高危、非转移性前列腺癌患者的治疗考虑。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/SURO.2002.35049

M. Eisenberger

{"title":"Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer.","authors":"M. Eisenberger","doi":"10.1053/SURO.2002.35049","DOIUrl":"https://doi.org/10.1053/SURO.2002.35049","url":null,"abstract":"The management of patients with high-risk, early-stage, prostate cancer represents a major challenge to all disciplines involved in the treatment of this common malignant neoplasm. Definition of the natural history of this disease, including the identification of key prognostic factors, in addition to the availability of active systemic therapeutic modalities for patients with advanced disease, are among the basic requirements that allow for early intervention in high-risk patients. Emerging new antiprogression approaches, targeted at various known stages of the metastatic cascade with the potential benefit of altering the natural history of early prostate cancer are attractive alternatives for early interventions with innovative programs. Studies on the natural history of patients with evidence of biochemical relapse following local treatment provide the basis for appropriate estimation of the risk ratio for development of clinical metastasis and selection of candidates for aggressive implementation of early treatment. The study of new candidate biomarkers of disease activity should be included in the context of clinical trials. Genotypic and phenotypic characterization of patients in clinical trials may enhance future therapeutic prospects in this disease.","PeriodicalId":79436,"journal":{"name":"Seminars in urologic oncology","volume":"20 3 Suppl 1 1","pages":"19-23"},"PeriodicalIF":0.0,"publicationDate":"2002-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"58399198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Editorial: the coming revolution in the treatment of prostate cancer patients. 社论:即将到来的前列腺癌治疗革命。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/SURO.2002.35050

D. Petrylak, R. de Wit

引用次数: 2

Magnetic resonance imaging of prostate cancer. 前列腺癌的磁共振成像。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/suro.2002.35333

Saroja Adusumilli, E Scott Pretorius

引用次数: 18

The utility of monoclonal antibodies in the imaging of prostate cancer. 单克隆抗体在前列腺癌影像学中的应用。

Seminars in urologic oncology Pub Date : 2002-08-01 DOI: 10.1053/suro.2002.36250

Daniel Yao, Edouard J Trabulsi, Lale Kostakoglu, Shankar Vallabhajosula, Maureen A Joyce, David M Nanus, Matthew Milowsky, He Liu, Stanley J Goldsmith

{"title":"The utility of monoclonal antibodies in the imaging of prostate cancer.","authors":"Daniel Yao, Edouard J Trabulsi, Lale Kostakoglu, Shankar Vallabhajosula, Maureen A Joyce, David M Nanus, Matthew Milowsky, He Liu, Stanley J Goldsmith","doi":"10.1053/suro.2002.36250","DOIUrl":"https://doi.org/10.1053/suro.2002.36250","url":null,"abstract":"<p><p>Monoclonal antibodies (mAbs) to prostate-specific antigens, such as PSMA, have great potential as diagnostic and therapeutic tools in the management of advanced prostate cancer. PSMA is a very attractive target for mAb-based imaging. It is expressed by virtually all prostate cancers and its expression is further increased in poorly differentiated, metastatic, and hormone-refractory carcinomas. The ProstaScint scan (Cytogen, Princeton, NJ), based on the mAb 7E11-C5.3, is currently approved for the imaging of prostate cancer in soft tissue but is not approved for imaging bone metastases. It appears superior to conventional imaging studies for soft-tissue disease but has limitations attributed to its intracellular binding site on PSMA. Overcoming this limitation, new mAbs to the extracellular domain of PSMA have been developed. The radioisotopes, (111)Indium, (90)Yttrium, and (177)Lutetium have been conjugated to one such mAb, J591. Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone.</p>","PeriodicalId":79436,"journal":{"name":"Seminars in urologic oncology","volume":"20 3","pages":"211-8"},"PeriodicalIF":0.0,"publicationDate":"2002-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21976977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 41

Validity of prognostic models: when is a model clinically useful? 预后模型的有效性:什么时候模型在临床上有用?

Seminars in urologic oncology Pub Date : 2002-05-01 DOI: 10.1053/SURO.2002.32521

Y. Vergouwe, E. Steyerberg, M. Eijkemans, J. Habbema

引用次数: 128

The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer. 前列腺癌局部治疗后PSA水平升高患者的困境。

Seminars in urologic oncology Pub Date : 2002-05-01 DOI: 10.1053/SURO.2002.32834

L. Lassiter, M. Eisenberger

{"title":"The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer.","authors":"L. Lassiter, M. Eisenberger","doi":"10.1053/SURO.2002.32834","DOIUrl":"https://doi.org/10.1053/SURO.2002.32834","url":null,"abstract":"Patients with a rising prostate-specific antigen (PSA) levels after definitive local therapy now represent one of the largest and fastest growing groups of men with prostate cancer. The great majority of these men are asymptomatic with no other evidence of disease, and their clinical outcomes have been widely variable and poorly understood. Recently, several groups have analyzed their institutions' data and reported on certain pathologic and clinical variables that have increased our understanding of the natural history of these men, and to some extent allowed for the development of predictive models to aid in deciding who should be treated more aggressively and who should be watched. This article reviews and critically evaluates the most relevant available data for this group of men, and offers a summary of the most useful models and predictive variables after both radical prostatectomy and radiotherapy. This article also offers recommendations for strategies to improve our current knowledge of the natural history of these men, to facilitate the development and implementation of clinical trials in this population, and to ultimately be able to offer the most appropriate recommendations to our patients in the clinic.","PeriodicalId":79436,"journal":{"name":"Seminars in urologic oncology","volume":"20 2 1","pages":"146-54"},"PeriodicalIF":0.0,"publicationDate":"2002-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"58398535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Artificial neural networks for diagnosis and prognosis in prostate cancer. 人工神经网络在前列腺癌诊断和预后中的应用。

Seminars in urologic oncology Pub Date : 2002-05-01 DOI: 10.1053/SURO.2002.32492

G. Schwarzer, M. Schumacher

引用次数: 46